UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Mar 19, 2025

Keywords

ClinConnect Summary

Primary Objective:

1. To generate a repository of participant-derived tumor models\* and specimens\*\* - annotated with demographic, clinical, and pathologic data - from adults with solid tumor malignancies with germline or somatic tumor-associated mutations and/or a personal or family history of cancer.

* Participant-derived models may include (but are not limited to) xenografts (PDX), organoids (PDO), and cell lines (PDCLs).

* Specimens may include tissue, ascites and pleural fluid, and blood.

Exploratory Objectives

1. To correlate in vivo drug sensitivity of participant-deri...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• For participants undergoing collection of tissue, ascites, and/or pleural effusions:
• • 1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.
• • 2. Individuals 18 years of age or older on the day of signing informed consent.
• • 3. Individuals with solid tumor malignancy with germline or somatic cancer-associated mutations and/or Individuals with a family history or personal history of cancer.
• 4. Must be planning to undergo one of the following procedures as part of their routine care (or as a research procedure under a UCSF-sponsored IIT protocol):
• • 1. Surgical resection
• • 2. Biopsy (open, incisional, excisional, punch, core needle, and/or fine needle aspiration (FNA) are all permitted)
• • 3. Paracentesis
• • 4. Thoracentesis
• For participants undergoing blood banking:
• • 1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.
• • 2. Individuals 18 years of age or older on the day of signing informed consent.
• • 3. Individuals with a family history or personal history of cancer.
• • 4. Must be planning to undergo a blood draw as part of their routine care (or as a research procedure under a University of California, San Francisco (UCSF) -sponsored investigator-initiated trial (IIT) protocol); or willing to undergo an additional blood draw outside of their routine care.
• Exclusion Criteria:
• • 1. Known history of HIV, Hepatitis B, or Hepatitis C (as documented in the medical record) or other infectious disease that in the judgment of the investigator could pose a risk to research personnel or mice, or negatively impact Patient derived xenografts (PDX) tumor engraftment.

Trial Officials